A Review of the Microcirculation in Skin in Patients With Chronic Venous Insufficiency: The Problem and the Evidence Available for Therapeutic Options

Abstract

Impairment of the cutaneous microcirculation is a major predisposing factor in inflammation and ulceration in patients with chronic venous insufficiency (CVI). Increase of capillary filtration rate predisposes to the formation of edema. Local lymphedema is a complication of CVI, often underdiagnosed. This review is focused on CVI but excludes the complication of ulceration. Treatment of microcirculatory dysfunction can be done by pharmacologic intervention or compression therapy or using a combination of both. This review is focused on drugs that have been evaluated by randomized prospective controlled trials. The following compounds are discussed: horse chestnut seed extracts, flavonoids, red vine leaves extracts, total triterpenic fraction of Centella asiatica (L), prociadins, calcium dobesilate, and pentoxifylline. The microcirculatory effects of compression therapy using bandages or stockings are also reviewed. The major microcirculatory effects that have been shown are the reduction of capillary filtration rate and improvements in levels of transcutaneous partial pressures of oxygen and carbon dioxide (TcPO₂ and TcPCO₂). Available data suggest that a combination of pharmacologic and compression therapy may have some additive effects.

Keywords

skin microcirculation chronic venous insufficiency compression therapy drug therapy

References

Hern S , Mortimer PS. Visualization of dermal blood vessels—capillaroscopy. Clin Exp Dermatol 1999;24: 473-478.

Humbert P , Sainthillier J-M , Mac-Ary S , Petitjen A , Creidi P , Aubin F. Capillaroscopy and videocapillaroscopy assessment of skin microcirculation: dermatologic and cosmetic approaches. J Cosmetic Dermatol 2005;4: 153-162.

Stüttgen G , Forsmann WG. Pharmacology of the microvasculature of the skin. In: Marchonini A , editor. Jadasohn’s Handbuch der Haut-und Geschlechtskrankheiten, Ergänzungswerk Band i/4B. Berlin, Germany: Springer; 1981. p. 379-446.

Braverman IM. The cutaneous microcirculation . J Investig Dermatol Symp Proc 2000;5: 3-9.

Hiller D , Hornstein OP. Moderne Methoden zur nichtinvasiven Untersuchung der Mikrozirkulation der Haut. Zentralbl Haut Geschlechtskrankh 1990;58: 2-25.

Tooke JE. Peripheral microvascular disease in diabetes . Diabetes Res Clin Pract 1996;30(Suppl): 61-65.

Tooke JE. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes . J Diabetes Complications 2000; 14: 197-200.

Mani R. Venous haemodynamics—a consideration of macro- and microvascular effects . Proc Inst Mech Eng [H] 1992;206: 109-115.

Mani R. Science of measurements in wound healing . Wound Repair Regen 1999;6;330-334.

10.

Hammad L. A study of the mechanical and microcirculatory properties of skin subject to venous ulceration. PhD thesis, University of Southampton, 2000.

11.

Stüttgen G , Schaefer H. Funktionelle Dermatologie. Berlin, Germany: Springer; 1973.

12.

Lewis T. The vessels of the human skin and their responses. London: Shaw & Sons; 1923.

13.

Chahl LA. Antidromic vasodilatation and neurogenic inflammation . Pharmacol Ther 1988;37: 275-300.

14.

Schechner JS , Braverman IM. Synchronous vasomotion in the human cutaneous microvasculature provides evidence for central modulation. Microvasc Res 1992;44: 27-32.

15.

Boulant JA , Dean JB. Temperature receptors in the central nervous system. Annu Rev Physiol 1986;48: 639-654.

16.

Kvernmo HD , Stefanovska A , Bracic M , Kirkeboen KA , Kvernebo K et al. Spectral analysis of the laser Doppler perfusion signal in human skin before and after exercise. Microvasc Res 1998;56: 173-182.

17.

Callejas JM , Manasanch J , ETIC Group . Epidemiology of chronic venous insufficiency of the lower limbs in the primary care setting. Int Angiol 2004;23: 154-163.

18.

Olivencia JA. Pathophysiology of venous ulcers: surgical implications, review, and update . Dermatol Surg 1999;25: 880-885.

19.

Fagrell B.

Microcirculatory disturbances—the final cause for venous leg ulcers?

Vasa 1982;11: 101-103.

20.

Neumann HAM , Veraart JCJM. Morphological and functional skin changes in postthrombotic syndrome. Wien Med Wochenschr 1994;144: 204-206.

21.

Leu AJ , Leu HJ , Franzeck UK , Bollinger A. Microvascular changes in chronic venous insufficiency—a review. Cardiovasc Surg 1995; 3: 237-245.

22.

Howlader MH , Smith PD. Microangiopathy in chronic venous insufficiency: quantitative assessment by capillary microscopy. Eur J Endovasc Surg 2003;26: 325-331.

23.

Stacey MC , Burnand KG , Bhogal BS , Black MM. Pericapillary fibrin deposits and skin hypoxia precede the changes of lipodermatosclerosis in limbs at increased risk of developing a venous ulcer. Cardiovasc Surg 2000;8: 372-380.

24.

Kolbach DN , Hamulyak K , Prins MH , Neumann MA , Cleutjens JP. Severity of venous insufficiency is related to the density of microvascular deposition of PAI-I, uPA and von Willebrand factor. Vasa 2004;33: 19-24.

25.

Stücker M , Falkenberg M , Reuther T , Altmeyer P , Lubbers DW. Local oxygen content in the skin is increased in chronic venous incompetence. Microvasc Res 2000;59: 99-106.

26.

Stücker M , Schöbe MC , Hoffmann K , Schultz-Ehrenburg U. Cutaneous microcirculation in skin lesions associated with chronic venous insufficiency. Dermatol Surg 1995;21: 877-882.

27.

Mani R , Dempster JD , White JE , et al. Non-invasive oxygen measurements—have they a role in the clinic? In: Ryan TJ , editor. Beyond occlusion: wound care proceedings, ICSS 136. London: Royal Society of Medicine; 1988. p. 45-54.

28.

Mani R , White JE , Barrett DF , Weaver PW. Tissue oxygenation, venous ulcers and fibrin cuffs. J R Soc Med 1989;82: 345-346.

29.

Mani R , Gorman FW , White JE. Transcutaneous measurements of oxygen tension at the edges of leg ulcers: preliminary communication. J R Soc Med 1986;79: 650-654.

30.

Jünger M , Steins A , Hahn M , Hafner HM. Microcirculatory dys-function in chronic venous insufficiency (CVI). Microcirculation 2000;7: S3-S12.

31.

Franzeck UK , Bollinger A , Huch R , Huch A. Transcutaneous oxygen tension and capillary morphologic characteristics and density in patients with chronic venous incompetence. Circulation 1984;70: 806-811.

32.

deGiorgio-Miller AM , Treharne LJ , McAnulty RJ , Coleridge Smith PD , Laurent GJ , Herrick SE. Procollagen type I gene expression and cell proliferation are increased in lipodermatosclerosis. Br J Dermatol 2005;152: 242-249.

33.

Roszinski S , Koser T , Wilhelm KP , Schmeller W. Oxygenation of the dermis and subcutis in dermatoliposclerosis. Vasa 1993;22: 297-305.

34.

Cheatle TR , Shami SK , Stibe E , Coleridge Smith PD , Scorr JH. Vasomotion in venous disease. J Royal Soc Med 1991;84: 261-263.

35.

Mlacak B , Blinc A , Gale N , Ivka B. Microcirculation disturbances in patients with venous ulcer before and after healing as assessed by laser Doppler flux-metry. Arch Med Res 2005;36: 480-484.

36.

Malanin K , Havu VK , Kolari PJ. Dynamics of cutaneous laser Doppler flux with concentration of moving blood cells and blood cell velocity in legs with venous ulcers and in healthy legs. Angiology 2004;55: 37-42.

37.

Stücker M , Steinbrügge J , Memmel U , Avermaele A , Altmeyer P. Disturbed vasomotion in chronic venous insufficiency. J Vasc Surg 2003;38: 522-527.

38.

Gschwandtner ME , Ambrozy E , Maric S , Willfort A , Schneider B , Bohler K , et al. Microcirculation is similar in ischaemic and venous ulcers. Microvasc Res 2001;62: 226-235.

39.

Ogrin R , Darzins P , Khalil Z. Use of the sensory nerve stimulator to accelerate healing of a venous leg ulcer with sensory nerve dys-function: a case study. Int Wound J 2005;2: 242-251.

40.

Jünger M , Hahn M , Klyscz T , Steins A. Microangiopathy in the pathogenesis of chronic venous insufficiency. Curr Probl Dermatol 1999;27: 124-129.

41.

Bergan JJ , Schmid-Schönbein GW. Therapeutic management of chronic venous insufficiency: microcirculation as a target. Microcirculation 2000;7: S23-S28.

42.

Eliska O , Elskova M. Morphology of lymphatics in human venous crural ulcers with lipodermatosclerosis. Lymphology 2001;34: 111-123.

43.

Trent JT , Falabella A , Eaglstein WH , Kirsner RS. Venous ulcers: pathophysiology and treatment options. Ostomy Wound Manage 2005;51: 38-54.

44.

Wilkinson JA , Brown AMG. Horse chestnut—Aesculus hippocastanum: potential applications in cosmetic skin-care products. Int J Cosmetic Sci 1999;21: 437-447.

45.

Monographie Roßkastaniensamen. Bundesanzeiger vom 15.04.1994.

46.

Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile . Pharmacol Res 2001;44: 183-193.

47.

Sato I , Suzuki T , Kobayashi H , Tsuda S. Antioxidative and antigenotoxic effects of Japanese horse chestnut (Aesculus turbinata) seeds. J Vet Med Sci 2005;67: 731-734.

48.

Wei F , Ma LY , Jin WT , Ma SC , Han GZ , Khan IA , et al. Antiinflammatory triterpenoid saponins from the seeds of Aesculus chinensis. Chem Pharm Bull (Tokyo) 2004;52: 1246-1248.

49.

Rehn D , Unkauf M , Klein P , Jost V , Lucker PW. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency. Arzneimittelforschung 1996;46: 483-487.

50.

Diehm C , Trampisch HJ , Lange S , Schmidt C. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996;347: 292-294.

51.

Ottillinger B , Greeske K. Rational therapy of chronic venous insufficiency—chances and limits of the therapeutic use of horse-chestnut seeds extract. BMC Cardiovasc Disord 2001;1: 5-5.

52.

Siebert U , Brach M , Sroczynski G , Berla K. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. Int Angiol 2002;21: 305-315.

53.

Ruffini I , Belcaro G , Cesarone MR , Dugall M. Efficacy of topical treatment with aescin + essential phospholipids gel in venous insufficiency and hypertension. Angiology 2004;55(Suppl 1): S19-S21.

54.

Ricci A , Ruffini I , Cesarone MR , Cornelli U , Corsi M , Belcaro G , et al. Variations in plasma free radicals with topical aescin + essential phospholipids gel in venous hypertension: new clinical data. Angiology 2004;55(Suppl 1): S11-S14.

55.

Cesarone MR , De Sanctis MT , Incandela L , Belcaro G , Griffin M. Microvascular changes in venous hypertension due to varicose veins after standardized application of Essaven gel—a placebo-controlled, randomized study. Angiology 2001;52(Suppl 3): S11-S16.

56.

Incandela L , Belcaro G , Cesarone MR , De Sanctis MT , Griffin M. Changes in microcirculation in venous ulcers with Essaven gel—a pilot, cross-over, placebo-controlled, randomized study. Angiology 2001;52(Suppl 3): S23-S27.

57.

Pittler MH , Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2006;1: CD003230.

58.

Tiffany N , Boon H , Ulbricht C , Basch E , Bent S , Barrette EP. Horse chestnut: a multidisciplinary clinical review. J Herb Pharmacother 2002;2: 71-85.

59.

Arturson G. Effects of O-(ß-hydroxyethyl)-rutosides (HR) on the increased microvascular permeability in experimental skin burns. Preliminary report . Acta Chir Scand 1972;138: 111-117.

60.

Hilton JG. Effects of ß-hydroxyethyl rutosides (H-R) administered post burn after thermal-injury-induced plasma volume loss in the nonresiscitated dog . Burns Incl Therm Inj 1982;8: 391-394.

61.

Roztocil K , Prerovsky I , Oliva I. The effect of hydroxylethylrutosides on capillary filtration rate in the lower limb of man. Eur J Clin Pharmacol 1977;11: 435-438.

62.

Ekestroem S , Welti R. The affinity of hydroxyethylrutosides for the venous wall and its efficacy in preventing early occlusions of aorto-coronary vein bypass grafts. Phlebology 1990;5(Suppl 1): 41-48.

63.

Arturson G , Jonsson CE. Stimulation and inhibition of biosyn-thesis of prostaglandins in human skin by some hydroxyethyletd rutosides. Prostaglandins 1975;10: 941-948.

64.

Alcaraz MJ , Ferràndiz ML. Modification of arachidonic metabolism by flavonoids. J Ethnopharmacol 1987;21: 209-229.

65.

Nees S. O-(β-hydroxyethyl)-rutosides (HR) protect vascular endothelium against oxidative injury . Int J Microcirc Clin Exper 1992;11(Suppl 1): S172-S172.

66.

Smith PD. Micronized purified flavonoid fraction and the treatment of chronic venous insufficiency: microcirculatory mechanisms . Microcirculation 2000;7: S35-S40.

67.

Nicolaides AN. From symptoms to leg edema: efficacy of Daflon 500 mg . Angiology 2003;54(Suppl 1): S33-S44.

68.

Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency . Angiology 2001;52(Suppl 1): S49-S56.

69.

Olszewski W. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema . Angiology 2000;51: 25-29.

70.

Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assessment and quality of life improvement with micronized flavonoids . Angiology 2002;53: 245-256.

71.

Danielsson G , Jungbeck C , Peterson K , Norgren L. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg 2002;23: 73-76.

72.

Ramelet AA. Daflon 500 mg: symptoms and edema clinical update . Angiology 2005;56(Suppl 1): S25-S32.

73.

Petruzzellis V , Troccoli T , Candiani C , Guarisca R , Lospalluh M , Belcaro G , et al. Oxerutins (Venoruton®): efficacy in chronic venous insufficiency—a double-blind, randomized, controlled study. Angiology 2002;53: 257-263.

74.

Incancela L , Belcaro G , Renton S , De Sanctis MT , Cesarone MR , Bavera P , et al. HR (Paroven, Venoruton; O-(beta-hydroxyethal)-ruto-sides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther 2002;7(Suppl 1): S7-S10.

75.

Cesarone MR , Incandela L , De Sanctis MT , Belcaro G , Dugall M , Acerbi G. Variations in plasma free radicals in patients with venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther 2002;7 (Suppl 1): S25-S28.

76.

Cesarone MR , Belcaro G , Pellegrini L , Ledda A , Di Renzo A , Vinciguerra A , et al. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study. Angiology 2005;56: 1-8.

77.

Cesarone MR , Belcaro G , Pellegrini L , Ledde A , Vinciguerra G , Ricci A , et al. HR, O-(beta-Hydroxyethyl)-rutosides; (Venoruton): rapid relief of signs/symptoms in chronic venous insufficiency and microangiopathy: a prospective controlled study. Angiology 2005;56: 165-172.

78.

Unkauf M , Rehn D , Klinger J , de la Motte S , Grassmam K , et al. Investigation on the efficacy of oxerutins compared to placebo in patients with chronic venous insufficiency treated with compression stockings. Arzneimittelforschung 1996;46: 478-482.

79.

Cesarone MR , Belcaro G , Pellegrini L , Ledda A , Vinciguerra G , Ricci A , et al. Venoruton vs. Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 2006;57: 131-138.

80.

Nees S , Weiss DR , Reichenbach-Klinke E , Dampp F , Heilmeier B , Kanbach J , et al. Protective effects of flavonoids contained in the red vine leaf on venular endothelium against the attack of activated blood components in vitro. Arzneimittelforschung 2003;53: 330-341.

81.

Schaefer E , Peil H , Ambrosetti L , Petrini O. Oedema protective properties of the red vine leaf extract AS 195 (Folia vitis viniferae) in the treatment of chronic venous insufficiency. A 6-week observational clinical trial. Arzneimittelforschung 2003;53: 243-246.

82.

Kalus U , Koscielny J , Grigorov A , Schaefer E , Peil H , Kiesewetter H , et al. Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study. Drugs R D 2004; 5: 63-71.

83.

Biswas TK , Mukherjee B. Plant medicines of Indian origin for wound healing activity: a review. Int J Lower Extremity Wounds 2003;2: 25-39.

84.

Shetty BS , Usupa SL , Udupa AL , Somayaji SN. Effect of Centella asiatica L (Umbelliferae) on normal and dexamethasone suppressed wound healing in Wistar albino rats. Int J Lower Extremity Wounds 2006; 5(3): 137-143.

85.

Belcaro G , Grimaldi R , Guidi G. Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. Angiology 1990;41: 533-540.

86.

Tenni R , Zanaboni G , De Agostini MP , Rossi A , Bendotti C , Cetta G. Effect of triterpenoid fraction of Centella asiatica on macromolecules of the connective tissue matrix in human skin fibroblast cultures. Ital J Biochem 1988;37: 69-77.

87.

Incandela L , Cesarone MR , Cacchio M , De Sanctis MT , Santavenere C , D’Auro MG , et al. Total triterpenic fraction of Centella asiatica in chronic venous insufficiency and in high-perfusion microangiopathy. Angiology 2001;52(Suppl 2): S9-S13.

88.

Montecchio GP , Samaden A , Carbone S , Vigotti M , Siragusa S , Divoella F. Centelle asiatica trierpenic fraction (CATTF) reduces the number of circulating endothelial cells in subjects with post phlebitic syndrome. Haematologica 1991;76: 256-259.

89.

Cesarone MR , Belcaro G , Rulo A , Griffin M , Ricci A , Ippolito E , et al. Microcirculatory effects of total triterpenic fraction of Centelle asiatica in chronic venous hypertension: measurement by laser Doppler, TcPO2-CO2, and leg volumetry. Angiology 2001;52(Suppl 2): S45-S48.

90.

Incandela L , Belcaro G , De Sanctis MT , Cesarone MR , Griffin M. Ippolito E , et al. Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model. Angiology 2001;52(Suppl 2): S61-S67.

91.

De Sanctis MT , Belcaro G , Incandela L , Cesarone MR , Griffin M , Ippolito E , et al. Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. Angiology 2001;52(Suppl 2): S55-S59.

92.

Cesarone MR , Laurora G , Pomante P , Belcaro G , Grimaldi R , Marelli C , et al. Efficacy of TTFCA in reducing the ratio between lymphatic and plasma protein concentration in lymphatic and postphlebitic edema [Italian]. Minerva Cardioangiol 1991;39: 475-478.

93.

Robert AM , Robert L , Renard G. Effect of procyanidolic oligomers of Vitis vinifera on the biosynthesis and excretion of corneal glycosaminoglycans. Pathol Biol (Paris) 2005;53: 411-415.

94.

Lagrue G , Olivier-Martin F , Grillot A. A study of the effects of procyanidol oligomers on capillary resistance in hypertension and in certain nephropathies [French]. Sem Hop 1981;57: 1399-1401.

95.

Henriet JP. Veno-lymphatic insufficiency. 4,729 patients undergoing hormonal and procyanidol oligomer therapy [French] . Phlebologie 1993;46: 313-325.

96.

Daroczy J , Pal A , Blasko G. Microcirculatory changes in patients with chronic venous and lymphatic insufficiency and heavy leg symptoms before and after therapy with procyanidol oligomers (Laser-Doppler study) [Hungarian]. Orv Hetil 2004;145: 1177-1181.

97.

Grimm T , Schäfer A , Hogger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med 2004;36: 811-822.

98.

Packer L , Rimbach G , Virgili F. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med 1999;27: 704-724.

99.

Kim YG , Park HY. The effects of pycnogenol on DNA damage in vitro and expression of superoxide dismutase and HP1 in Escherichia coli SOD and catalase deficient mutant cells. Phytother Res 2004;18: 900-905.

100.

Peng Q , Wei Z , Lau BH. Pycnogenol inhibits tumor necrosis factor-alpha-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 2000;57: 834-841.

101.

Araghi-Niknam M , Hosseini S , Larson D , Rohdewald P , Watson RR. Pine bark extract reduces platelet aggregation. Integr Med 2000;2: 73-77.

102.

Schäfer A , Chovanova Z , Muchova J , Sumegova K , Liptakova A , Durackova C , et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 2006;60: 5-9.

103.

Blazso G , Gabor M , Schönlau F , Rohdewald P. Pycnogenol accelerates wound healing and reduces scar formation. Phytother Res 2004;18: 579-581.

104.

Koch R. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency . Phytother Res 2002;16(Suppl 1): S1-S5.

105.

Arcangeli P. Pycnogenol in chronic venous insufficiency . Fitoterapia 2000;71: 236-244.

106.

Petrassi C , Mastromarino A , Spartera C. Pycnogenol in chronic venous insufficiency. Phytomedicine 2000;7: 383-388.

107.

Belcaro G , Cesarone MR , Errichi BM , Ledda A , Di Renzo A , Stuard S , et al. Venous ulcers: microcirculatory improvement and faster healing with local use of pycnogenol. Angiology 2005;56: 699-705.

108.

Tejerina T , Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol 1998;31: 357-360.

109.

Arceo A , Berber A , Trevino C. Clinical evaluation of the efficacy and safety of calcium dobesilate in patients with chronic venous insufficiency of the lower limbs. Angiology 2002;53: 539-544.

110.

Marinello J , Videla S , Group for the Assessment of the Transcutaneous Oxygen Pressure in Chronic Venous Insufficiency . Chronic venous insufficiency of the lower limbs: suitability of transcutaneous blood gas monitoring as an endpoint to evaluate the outcome of pharmacological treatment with calcium dobesilate. Methods Find Exp Clin Pharmacol 2004;26: 775-780.

111.

Ciapponi A , Laffaire E , Roque M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology 2004; 55: 147-154.

112.

Müller R. Pentoxifylline—a biomedical profile . J Med 1979; 10: 307-329.

113.

Angelides NS , Weil von der Ahe CA. Effect of oral pentoxifylline therapy on venous lower extremity ulcers due to deep venous incompetence. Angiology 1989;40: 752-763.

114.

Angelides NS , von der Ahe CW , Themistocleus P. Comparison of skin and muscle biopsies before and after pentoxifylline treatment in patients with leg ulcers due to deep venous incompetence. Int Angiol 1991;10: 72-76.

115.

De Sanctis MT , Belcaro G , Cesarone MR , Ippolito E , Nicolaides AN , Incandela L , et al. Treatment of venous ulcers with pentoxifylline: a 12-month, double-blind, placebo controlled trial. Microcirculation and healing. Angiology 2002;53(Suppl 1): S49-S51.

116.

Stücker M , Huntermann C , Bechara FG , Hoffmann K , Altmeyer P. Capillary blood cell velocity in periulcerous regions of the lower leg measured by laser Doppler anemometry. Skin Res Technol 2004;10: 174-177.

117.

Falanga V , Fujitani RM , Diaz C , Hunter G , Jorizzo J , Lawrence PF , et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999;7: 208-213.

118.

Oduncu H , Clark M , Williams RJ. Effect of compression on blood flow in lower limb wounds. Int Wound J 2004;1: 107-113.

119.

Jünger M , Sippel K. Compression therapy in chronic venous insufficiency. New test procedures and therapeutic options. Hautarzt 2003;54: 1045-1052.

120.

Abu-Own A , Shami SK , Chittenden SJ , Farrah J , Scurr JH , Smith PD. Microangiopathy of the skin and the effect of leg compression in patients with chronic venous insufficiency. J Vasc Surg 1994;19: 1074-1083.

121.

Gniadecki R , Gniadecka M , Kotowski T , Serup J. Alterations of skin microcirculatory rhythmic oscillations in different positions of the lower extremity. Acta Derm Venereol 1992;72: 259-260.

122.

Klyscz T , Galler S , Steins A , Zuder D , Rassner G , Junger M. The effect of compression therapy on the microcirculation of the skin in patients with chronic venous insufficiency (CVI). Hautarzt 1997;48: 806-811.

123.

Badger C , Preston N , Seers K , Mortimer P. Physical therapies for reducing and controlling lymphedema of the limbs. Cochrane Database Syst Rev 2004;4: CD003141.

124.

Amann-Vesti BR , Ruesch C , Gitzelmann G , Hafner J , Koppensteiner R. Microangiopathy of split-skin grafts in venous ulcers. Dermatol Surg 2004;30: 399-402.